MRK Merck & Co.
Merck’s diversified drug portfolio and strong cash flow support steady growth, but patent cliffs cap upside.
The business
Merck develops, manufactures, and markets prescription medicines, vaccines, and animal health products worldwide, earning revenue from sales and royalties of its drug portfolio.
Quality gate · 85/100
Moat & management
| Moat | narrow moat |
| Source | intangible |
| Trajectory | stable |
| Management | excellent |
Patents, regulatory approvals, and a strong brand protect individual products, while a broad pipeline and global scale provide some cushion, but each drug faces eventual expiry.
Consistently returns cash to shareholders via dividends and buybacks, maintains a disciplined R&D spend, and pursues selective acquisitions.
Owner-earnings inputs
| Owner earnings (TTM) | 11.41B |
| Owner-earnings yield | 3.7% |
| Free-cash-flow yield | 4.6% |
| Growth used (normalized) | 7.0% |
| Market-implied growth (reverse DCF) | 10.8% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 12.21B | 7.0% | 11.20B |
| 2 | 13.03B | 6.7% | 10.97B |
| 3 | 13.87B | 6.4% | 10.71B |
| 4 | 14.72B | 6.1% | 10.43B |
| 5 | 15.58B | 5.9% | 10.13B |
| 6 | 16.45B | 5.6% | 9.81B |
| 7 | 17.32B | 5.3% | 9.47B |
| 8 | 18.18B | 5.0% | 9.13B |
| 9 | 19.04B | 4.7% | 8.77B |
| 10 | 19.89B | 4.4% | 8.40B |
| 11 | 20.71B | 4.1% | 8.03B |
| 12 | 21.51B | 3.9% | 7.65B |
| 13 | 22.28B | 3.6% | 7.27B |
| 14 | 23.01B | 3.3% | 6.89B |
| 15 | 23.70B | 3.0% | 6.51B |
Key risks
- Keytruda patent cliff
- Competitive pressure on new drugs
- Regulatory and pricing headwinds
- R&D pipeline failure
Catalysts
- Approval of next‑generation oncology agents
- Successful vaccine launches
- Strategic acquisitions to broaden pipeline
Recent news
score · 8 articles
- Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
- Merck (MRK) Declines More Than Market: Some Information for Investors
- Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
- Reading Between The Lines Of JNJ Stock's Latest Call
- Eli Lilly Stock And The Price Of Confidence
- Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug
- The Real Question Buried Inside Merck Stock's Premium Price
- Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~11%/yr owner-earnings growth over 15y (reverse DCF); model credits 7%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.